Efficacy and Safety of CLAG-Based Sequential Conditioning Followed by Allogeneic Hematopoietic Stem Cell Transplantation in Non-Remission Relapsed or Refractory Acute Leukemia [0.03%]
基于CLAG方案序贯预处理后异基因造血干细胞移植治疗难治复发急性白血病的有效性和安全性
Shiyu Chen,Xiaohan Zhang,Xiaoqing Li et al.
Shiyu Chen et al.
Background: The optimal bridge-to-transplant strategy for patients with relapsed or refractory (R/R) acute leukemia who remain in non-remission (NR) is undefined. We evaluated the strategy-level use of CLAG (cladribine, c...
Long-Term Results of Busulfan Plus High-Dose Idarubicin as a Conditioning Regimen to Autologous Stem Cell Transplantation Following Cytarabine Consolidation in Young Patients with Favorable or Intermediate-Risk Acute Myeloid Leukemia [0.03%]
细胞减积后采用白消安和大剂量伊达比星作为预处理方案进行自体干细胞移植治疗 favorable或intermediate-risk急性髓系白血病的年轻患者的长期疗效
Zixing Lu,Yayi Liu,Zhaoqing Jiang et al.
Zixing Lu et al.
Objective: To evaluate the long-term efficacy and safety of high-dose idarubicin plus busulfan (I-Bu) conditioning followed by autologous stem cell transplantation (ASCT) compared to intermediate- to high-dose cytarabine ...
Risk and Survival Outcomes of Secondary Primary Malignancies in Chinese Lymphoma Patients in the Era of Modern Targeted Therapies: A Single-Center Retrospective Cohort Study [0.03%]
靶向治疗时代中国淋巴瘤患者继发恶性肿瘤的风险及预后：单中心回顾性队列研究
Chen Qiu,Tingting Zhang,Xuejing Yang et al.
Chen Qiu et al.
Introduction: With the advent of modern therapies, including rituximab and novel oral targeted agents such as BTK inhibitors, the survival of lymphoma patients has significantly improved. However, the risk of secondary pr...
Metabolic Subtypes Predict Treatment Response in Acute Myeloid Leukemia: A Pilot Study [0.03%]
代谢亚型预测急性髓系白血病治疗反应的初步研究
Changjian Yan,Yan Huang,Qing Cai et al.
Changjian Yan et al.
Introduction: To establish a dynamic metabolic subtyping system for acute myeloid leukemia (AML) based on longitudinal metabolomics and multi-omics integration, and to evaluate its ability to predict treatment response. ...
A Risk Model Using Refined Disease Risk Index and 1-Month NK-Cell Count for Relapse in Children and Adults with T-ALL/LBL After Myeloablative Umbilical Cord Blood Transplantation [0.03%]
改良的疾病风险指数和移植后1个月NK细胞计数预测T细胞急性淋巴细胞白血病/淋巴瘤接受脐带血造血干细胞移植后复发的风险模型
Na Zhao,Rong Chi,Kaidi Song et al.
Na Zhao et al.
Purpose: To assess transplant outcomes after umbilical cord blood transplantation (UCBT) in patients with T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL) and identify factors associated with relapse...
Exploring the Bone Marrow Microenvironment as a Therapeutic Barrier and Targetable Source of Crosstalk in Acute Myeloid Leukemia [0.03%]
探索骨髓微环境作为急性髓系白血病治疗障碍和可靶向的信号转导来源
Aleksandra Kolosova,Imogen Anna Mould,Chris Pepper et al.
Aleksandra Kolosova et al.
Acute myeloid leukemia (AML) is an aggressive and genetically heterogeneous hematological malignancy characterized by the accumulation of immature myeloid blasts that disrupt healthy hematopoiesis. Despite advances in molecular profiling an...
Short-Term Longitudinal Analysis of Gut Microbiota Dynamics During Anti-CD19 CAR-T Cell Therapy in Diffuse Large B-Cell Lymphoma Patients [0.03%]
弥漫大B细胞淋巴瘤患者抗CD19CAR-T细胞治疗的短期纵向肠道菌群动态分析
Ziyuan Shen,Xing Xing,Kang Rong et al.
Ziyuan Shen et al.
Purpose: Alterations in gut microbiota may influence immune response and treatment outcomes in patients with diffuse large B-cell lymphoma (DLBCL). However, the dynamics during anti-CD19 CAR-T cell therapy remain unclear....
Poor Outcome of Pediatric Patients with Acute Lymphoblastic Leukemia Harboring Low P16 Deletion Ratio: A Post-Hoc Analysis from a Prospective Cohort [0.03%]
低P16基因缺失比率的儿童急性淋巴细胞白血病患者预后不良：一项前瞻性队列的事后分析研究
Kun-Yin Qiu,Xiong-Yu Liao,Hai-Lei Chen et al.
Kun-Yin Qiu et al.
Object: The prognostic significance of P16 (CDKN2A) deletion (P16del ) in pediatric acute lymphoblastic leukemia (ALL) remains controversial, potentially due to the historical reliance on binary classification. ...
Defining High-Risk Disease Biology in Multiple Myeloma: A Narrative Review [0.03%]
定义多发性骨髓瘤高危疾病生物学：叙述性综述
Mohammad Aljumaa,Hasan Hamam Refai,Yogesh Chawla et al.
Mohammad Aljumaa et al.
Although modern therapies have significantly improved survival, multiple myeloma (MM) remains incurable and biologically heterogeneous, resulting in substantial variability in treatment response and outcomes. Effective risk stratification i...
Enzymatic Laccase Nanoreactors Induce Apoptosis in MOLT-4-ALL Cells and Activate Prodrugs in a Synergetic Effect [0.03%]
基于辣木酶的纳米反应器诱导白血病细胞凋亡及活化前药的作用机制研究
Carlos A Medrano-Villagómez,Elizabeth Loredo-García,Jahaziel Gasperin-Bulbarela et al.
Carlos A Medrano-Villagómez et al.
Introduction: The search for novel cancer treatment strategies is of great interest. Recently, it has been reported that laccases from various sources exhibit anti-tumor effects. In addition, the use of nanometric platfor...